Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | KCNQ3 | O43525 | 4/20 | 0.35 |
| ▸ | KCNQ2 | O43526 | 4/20 | 0.35 |
| ▸ | KCNE1 | P15382 | 3/20 | 0.35 |
| ▸ | KCNQ1 | P51787 | 3/20 | 0.35 |
| ▸ | BACE1 | P56817 | 1/20 | 0.35 |
| ▸ | PTH1R | Q03431 | 4/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | TNF | P01375 | 1/20 | 0.33 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24375404 | 0.82 | PTH1R (0.33) | MAPTPTH1R | |
| SCHEMBL20934880 | 0.73 | APP (0.39) | MAPTPTH1RALDH1A1 | |
| SCHEMBL26406348 | 0.73 | MAPT (0.59) | MAPTPTH1RALDH1A1 | |
| SCHEMBL20934767 | 0.73 | FPR2 (0.37) | MAPTALDH1A1 | |
| SCHEMBL19796165 | 0.72 | KCNQ3 (0.44) | MAPTKCNQ3KCNQ2KCNE1KCNQ1 | |
| SCHEMBL9218436 | 0.71 | STK17A (0.51) | — | |
| SCHEMBL7662714 | 0.71 | RRM2 (0.44) | MAPTKCNQ3KCNQ2KCNE1KCNQ1 | |
| SCHEMBL9220618 | 0.71 | STK17A (0.44) | MAPTKCNQ3KCNQ2KCNE1KCNQ1 | |
| SCHEMBL17604124 | 0.71 | KCNQ3 (0.46) | MAPTKCNQ3KCNQ2KCNE1KCNQ1 | |
| SCHEMBL19796124 | 0.69 | MAPT (0.46) | MAPTKCNQ3KCNQ2KCNE1KCNQ1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230019491-A1 | PYRIMIDINE TBK/IKKe INHIBITOR COMPOUNDS AND USES THEREOF | EMD Serono Research and Development Institute, Inc. | 2023-01-19 | — | — | US | disclosed |
| WO-2019079373-A1 | PYRIMIDINE TBK/IKKε INHIBITOR COMPOUNDS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2019-04-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230019491-A1 | PYRIMIDINE TBK/IKKe INHIBITOR COMPOUNDS AND USES THEREOF | DTYMK, TBKBP1, NFKBIA | MAPT 1313/4885KCNQ3 3200/4885KCNQ2 2557/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.